Medpace (NASDAQ:MEDP) Shares Down 3.7% on Insider Selling

Medpace Holdings, Inc. (NASDAQ:MEDP) shares fell 3.7% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $530.96 and last traded at $554.93. 157,218 shares traded hands during trading, a decline of 61% from the average session volume of 408,083 shares. The stock had previously closed at $576.49.

Specifically, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 23,178 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $593.25, for a total transaction of $13,750,348.50. Following the completion of the sale, the chief executive officer directly owned 652,550 shares of the company’s stock, valued at $387,125,287.50. This represents a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other Medpace news, CEO August J. Troendle sold 15,151 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $593.46, for a total transaction of $8,991,512.46. Following the transaction, the chief executive officer owned 675,728 shares in the company, valued at $401,017,538.88. This represents a 2.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Mizuho boosted their price target on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their price target for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $487.18.

Medpace Price Performance

The business’s fifty day moving average price is $566.87 and its 200 day moving average price is $451.00. The stock has a market cap of $15.35 billion, a P/E ratio of 38.10, a PEG ratio of 2.17 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Clarkston Capital Partners LLC acquired a new position in shares of Medpace during the second quarter worth $40,569,000. Nordea Investment Management AB increased its holdings in Medpace by 4.8% in the second quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock valued at $19,067,000 after purchasing an additional 2,792 shares during the period. Arkadios Wealth Advisors bought a new position in Medpace during the 2nd quarter worth $327,000. Inspire Investing LLC acquired a new position in Medpace during the 1st quarter worth about $2,059,000. Finally, Truist Financial Corp lifted its holdings in Medpace by 10.2% during the 2nd quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock worth $4,048,000 after buying an additional 1,197 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.